Abacus Parenteral Drugs Limited

abacusparenteral.com

Trading in pharmaceutical products is one of core industry in Uganda‘s economy. As the manufacturers of pharmaceutical products are very few to cater the market demand, majority of demand was met through importation. This business is growing at a rapid pace with the growth of population and export potential to neighbour countries like Kenya, Rwanda, Burundi, Congo, Sudan etc. Nonetheless the Government support by removal of taxes on imports of Pharmaceutical products, to sustain its policies of providing proper medication to people, also provided a vital support for its accelerating growth.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA SEES MORE POST-M&A REBRANDS THAN OTHER INDUSTRIES—AND IT DOES THEM BETTER, TOO

Fiercepharma | June 03, 2020

news image

To rebrand or not? It’s a big question for pharma companies before and after acquisitions—and one answered with "yes" more often than in other industries. Pharma, in fact, was the most prolific rebrander in Brand Finance’s recent research assessing the value of rebrands across 25 industries. It's also one of the most successful, with rebrands in pharma generating average returns of 13.8%, according to Brand Finance calculations. The main reason? Most acquired phar...

Read More

Pharma Tech

BAYER AND MAMMOTH BIOSCIENCES TO COLLABORATE ON NOVEL GENE EDITING TECHNOLOGY

Bayer and Mammoth Biosciences | January 10, 2022

news image

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop tra...

Read More

Business Insights

INTEGRITY BIO AND LAKEPHARMA BECOME CURIA

Curia | February 15, 2022

news image

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand. This change reflects the accelerated organizational integration of the acquired companies into Curia and its provision of comprehensive biologics discovery, development and manufacturing solutions to customers. Curia completed the acquisition of Integrity Bio in August 2021...

Read More

Pharmacy Market

STANDIGM SIGNS MOU WITH MERCK KOREA FOR AI DRUG DISCOVERY RESEARCH

Standigm | June 02, 2022

news image

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research. The MOU signing took place on May 30 at the headquarters of Standigm, attended by Sojeong Yun, CEO of Standigm, and Stephen Namkoo Lee, the Head of Science and Lab Solutions, Life Science business sector of Merck Korea. Under the MOU, Standigm will accelerate its drug discovery r...

Read More
news image

PHARMA SEES MORE POST-M&A REBRANDS THAN OTHER INDUSTRIES—AND IT DOES THEM BETTER, TOO

Fiercepharma | June 03, 2020

To rebrand or not? It’s a big question for pharma companies before and after acquisitions—and one answered with "yes" more often than in other industries. Pharma, in fact, was the most prolific rebrander in Brand Finance’s recent research assessing the value of rebrands across 25 industries. It's also one of the most successful, with rebrands in pharma generating average returns of 13.8%, according to Brand Finance calculations. The main reason? Most acquired phar...

Read More
news image

Pharma Tech

BAYER AND MAMMOTH BIOSCIENCES TO COLLABORATE ON NOVEL GENE EDITING TECHNOLOGY

Bayer and Mammoth Biosciences | January 10, 2022

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop tra...

Read More
news image

Business Insights

INTEGRITY BIO AND LAKEPHARMA BECOME CURIA

Curia | February 15, 2022

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand. This change reflects the accelerated organizational integration of the acquired companies into Curia and its provision of comprehensive biologics discovery, development and manufacturing solutions to customers. Curia completed the acquisition of Integrity Bio in August 2021...

Read More
news image

Pharmacy Market

STANDIGM SIGNS MOU WITH MERCK KOREA FOR AI DRUG DISCOVERY RESEARCH

Standigm | June 02, 2022

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research. The MOU signing took place on May 30 at the headquarters of Standigm, attended by Sojeong Yun, CEO of Standigm, and Stephen Namkoo Lee, the Head of Science and Lab Solutions, Life Science business sector of Merck Korea. Under the MOU, Standigm will accelerate its drug discovery r...

Read More